MRNS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MRNS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Marinus Pharmaceuticals's EBITDA for the three months ended in Sep. 2024 was $-20.25 Mil. Marinus Pharmaceuticals's Revenue for the three months ended in Sep. 2024 was $8.54 Mil. Therefore, Marinus Pharmaceuticals's EBITDA margin for the quarter that ended in Sep. 2024 was -237.07%.
The historical data trend for Marinus Pharmaceuticals's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Marinus Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EBITDA Margin % | Get a 7-Day Free Trial | - | -3,908.09 | -624.56 | -20.95 | -404.97 |
Marinus Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
EBITDA Margin % | Get a 7-Day Free Trial | -389.59 | -519.42 | -445.27 | -385.69 | -237.07 |
For the Biotechnology subindustry, Marinus Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Marinus Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Marinus Pharmaceuticals's EBITDA Margin % falls into.
EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.
Marinus Pharmaceuticals's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as
Marinus Pharmaceuticals's EBITDA Margin % for the quarter that ended in Sep. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Marinus Pharmaceuticals (NAS:MRNS) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Thank you for viewing the detailed overview of Marinus Pharmaceuticals's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Christina Shafer | officer: Chief Commercial Officer | 5 RADNOR CORPORATE CENTER, SUITE 500, 100 MATSONFORD ROAD, RADNOR PA 19087 |
Scott Braunstein | director | C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108 |
Steven Pfanstiel | officer: CFO | 5 RADNOR CORPORATE CENTER STE 500, 100 MATSONFORD RD, RADNOR PA 19087 |
Joseph Hulihan | officer: Chief Medical Officer | 5 RADNOR CORP CENTER SUITE 500, 100 MATSONFORD RD, RADNOR PA 19087 |
Martha E Manning | officer: VP, Gen. Counsel & Corp. Sec. | 700 PENNSYLVANIA DR, EXTON PA 19341 |
Sarah B. Noonberg | director | 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Marvin Johnson | director | C/O TREVENA, INC., 955 CHESTERBROOK BOULEVARD, STE. 110, CHESTERBROOK PA 19087 |
Elan Ezickson | director | AVEO PHARMACEUTICALS, INC., 75 SIDNEY STREET, CAMBRIDGE MA 02139 |
Charles Austin | director | 5 RADNOR CORPORATE CENTER STE 500, 100 MATSONFORD RD, RADNOR PA 19087 |
Fischer Seth H.z. | director | C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121 |
Christine Berni Silverstein | director | C/O ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019 |
Santiago Arroyo | director | C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142 |
Sara Nochur | director | 295 WOODCLIFF RD, NEWTON MA 02461 |
Nicole Vitullo | director, 10 percent owner | 3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121 |
Edward F Smith | officer: Chief Financial Officer | C/O POLYMEDIX, INC., 3701 MARKET STREET, PHILADELPHIA PA 19104 |
From GuruFocus
By Marketwired • 07-31-2024
By Business Wire • 10-08-2024
By Marketwired • 08-02-2024
By Business Wire • 08-13-2024
By Business Wire • 09-12-2024
By GuruFocus Research • 08-14-2024
By PRNewswire • 08-02-2024
By Business Wire • 10-15-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.